Aptevo spotlights tumor-targeted CD40 multispecific program at SITC 2026 meeting

PUBT · 2d ago
Aptevo spotlights tumor-targeted CD40 multispecific program at SITC 2026 meeting
  • Aptevo Therapeutics announced a presentation at the SITC 2026 Annual Meeting highlighting its CD40-directed multispecific cancer immunotherapy platform.
  • Results have not been presented yet; the data are scheduled for November 4-8, 2026, with slides to be posted afterward.
  • The work targets solid tumors by concentrating immune activation in the tumor microenvironment to strengthen anti-tumor responses while limiting systemic activation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief on October 14, 2026, and is solely responsible for the information contained therein.